Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice
Nicola Garrett, … , Mark Simmons, Guillermina Girardi
Nicola Garrett, … , Mark Simmons, Guillermina Girardi
Published April 19, 2018
Citation Information: JCI Insight. 2018;3(8):e120147. https://doi.org/10.1172/jci.insight.120147.
View: Text | PDF
Research Article Reproductive biology Vascular biology

Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice

  • Text
  • PDF
Abstract

Preeclampsia (PE), associates with long-term increased risk for cardiovascular disease in women, suggesting that PE is not an isolated disease of pregnancy. It is not known if increased risk for long-term diseases is due to PE-specific factors or to prepregnancy renal and cardiovascular risk factors. We used a mouse model in which a WT female with normal prepregnancy health develops PE to investigate if preeclampsia causes long-term cardiovascular consequences after pregnancy for mothers and offspring. Mothers exhibited endothelial dysfunction and hypertension after PE and had glomerular injury that not only persisted but deteriorated, leading to fibrosis. Left ventricular (LV) remodeling characterized by increased collagen deposition and MMP-9 expression and enlarged cardiomyocytes were also detected after PE. Increased LV internal wall thickness and mass, increased end diastolic and end systolic volumes, and increased stroke volume were observed after PE in the mothers. Placenta-derived bioactive factors that modulate vascular function, markers of metabolic disease, vasoconstrictor isoprostane-8, and proinflammatory mediators were increased in sera during and after a preeclamptic pregnancy in the mother. Offspring of PE mice developed endothelial dysfunction, hypertension, and signs of metabolic disease. Microglia activation was increased in the neonatal brains after PE, suggesting neurogenic hypertension in offspring. Prevention of placental insufficiency with pravastatin prevented PE-associated cardiovascular complications in both mothers and offspring. In conclusion, factors that develop during PE have long-term, cardiovascular effects in the mother and offspring independent of prepregnancy risk factors.

Authors

Nicola Garrett, Joaquim Pombo, Michelle Umpierrez, James E. Clark, Mark Simmons, Guillermina Girardi

×

Figure 6

Signs of microglia activation in the brains of offspring born to preeclampsia mothers.

Options: View larger image (or click on image) Download as PowerPoint
Signs of microglia activation in the brains of offspring born to preecla...
(A) Expression of ionized calcium-binding adaptor molecule 1 (Iba-1) — a marker of activated microglia — in neonatal brains (P30) from pups born to control mothers and mothers with PE (untreated and treated with pravastatin). Increased Iba-1 staining is observed in the brains of offspring born to PE mothers. Ten slides per experimental group (5–7 mice/experimental group) were analyzed. Scale bar: 20 μm. Staining quantification was performed using ImageJ, and comparisons between groups were performed by 1-way ANOVA with Bonferroni’s post hoc test (C1q+/+: 9.8 ± 2.1 AU, C1q+/–: [control] 12 ± 2.3 AU, C1q+/– [PE]: 53* ± 14 AU [P < 0.05], C1q+/– [PE+PRAV]: 11 ± 3.2 AU; P < 0.05, different from C1q+/+). (B) The percentage of activated cells in immunopurified microglia isolated from P10 pups born to control mothers and PE mothers (untreated and treated with pravastatin during pregnancy). Four brains were dissected from the same litter and pooled for microglia isolation (n = 5–6 litters). Resting, nonactivated cells were identified by a small soma and ramified long thin processes (B, left inset). Activated microglia were less ramified and oval amoeboid-shaped cells (B, right inset). Scale bar: 10 μm. The number of activated microglia expressed as a percentage of the total number of microglia was used as a measure for microglial activation. (C) To evaluate the proinflammatory phenotype in microglia, microglial cells isolated from pups born to mothers subjected to normal and abnormal pregnancies (untreated and treated with pravastatin) were exposed to 1 μg/ml LPS in the culture medium for 24 hours. The supernatants were collected and measured for the presence of proinflammatory cytokines TNF-α and IL-6 by ELISA. Microglia isolated from pups born to untreated PE mothers showed an increased release of TNF-α and IL-6 in response to LPS indicative of a proinflammatory M1 phenotype. (B and C) Four brains were dissected from pups from the same litter and pooled for microglia isolation (n = 5–6 litters/ experimental group). Comparisons between groups were performed by 1-way ANOVA with Bonferroni’s post hoc test. *P < 0.01, different from control groups.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts